Repros Therapeutics (NASDAQ:RPRX) versus TG Therapeutics (TGTX) Head to Head Contrast

TG Therapeutics (NASDAQ: TGTX) and Repros Therapeutics (NASDAQ:RPRX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, analyst recommendations, profitability and earnings.

Valuation & Earnings

This table compares TG Therapeutics and Repros Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
TG Therapeutics $150,000.00 5,016.15 -$78.25 million ($1.93) -5.52
Repros Therapeutics $50,000.00 522.19 -$17.27 million ($0.50) -1.32

Repros Therapeutics has lower revenue, but higher earnings than TG Therapeutics. TG Therapeutics is trading at a lower price-to-earnings ratio than Repros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

50.4% of TG Therapeutics shares are held by institutional investors. Comparatively, 13.6% of Repros Therapeutics shares are held by institutional investors. 16.7% of TG Therapeutics shares are held by company insiders. Comparatively, 2.5% of Repros Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations for TG Therapeutics and Repros Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TG Therapeutics 0 0 9 0 3.00
Repros Therapeutics 0 1 0 0 2.00

TG Therapeutics presently has a consensus target price of $27.19, suggesting a potential upside of 155.28%. Repros Therapeutics has a consensus target price of $0.39, suggesting a potential downside of 40.91%. Given TG Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe TG Therapeutics is more favorable than Repros Therapeutics.

Profitability

This table compares TG Therapeutics and Repros Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
TG Therapeutics -73,217.77% -151.21% -116.84%
Repros Therapeutics -4,242.73% -894.22% -230.71%

Volatility & Risk

TG Therapeutics has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. Comparatively, Repros Therapeutics has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500.

Summary

TG Therapeutics beats Repros Therapeutics on 10 of the 14 factors compared between the two stocks.

TG Therapeutics Company Profile

TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti- programmed cell death ligand 1 (PD-L1) and anti- glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies.

Repros Therapeutics Company Profile

Repros Therapeutics, Inc. is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. The Company’s Proellex product candidate for female reproductive health is a chemical entity, which acts as a selective blocker of the progesterone receptor. It is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis The Company has an active Investigational New Drug (IND) for the vaginal delivery of Proellex for the treatment of uterine fibroids.

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply